oa mRNA Vaccines for COVID-19: A Simple Explanation

References

1. McKechnie JL, Blish CA. The innate immune system: fighting on the front lines or fanning the flames of COVID-19? Cell Host Microbe 2020; 27:(6):863–869. doi: 10.1016/j.chom.2020.05.009.
   [Google Scholar]
2. Stögerer T, Stäger S. Innate immune sensing by cells of the adaptive immune system. Front Immunol 2020; 11::1081. doi:10.3389/fimmu.2020.01081.
   [Google Scholar]
3. Ratajczak W, Niedz'wiedzka-Rystwej P, Tokarz-Deptuła B, Deptuła W. Immunological memory cells. Cent Eur J Immunol 2018; 43:(2):194–203. doi:10.5114/ceji.2018.77390.
   [Google Scholar]
4. Hendaus MA. Remdesivir in the treatment of coronavirus disease 2019 (COVID-19): a simplified summary. J Biomol Struct Dyn 2020:1–6. doi: 10.1080/07391102.2020.1767691.
   [Google Scholar]
5. De Gregorio E, Rappuoli R. Vaccines for the future: learning from human immunology. Microb Biotechnol 2012; 5:(2):149–155. doi:10.1111/j.1751-7915.2011.00276.x.
   [Google Scholar]
6. Pardi N, Hogan MJPorter FW,Weissman D. mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov 2018; 17:(4):261–279. doi:10.1038/nrd.2017.243.
   [Google Scholar]
7. Samrat SK, Tharappel AMLi Z,Li H Prospect of SARS-CoV-2 spike protein: Potential role in vaccine and therapeutic development. Virus Res 2020; 288::198141. doi:10.1016/j.virusres.2020.198141.
   [Google Scholar]
8. Center for Disease Control and Prevention. Understanding how COVID-19 vaccines work [Internet]. 2020 [updated 2021 Jan 13]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/how-they-work.html.
   [Google Scholar]
9. De Varona P. 5 experts explain mRNA vaccines for non-science people [Internet]. 2020 Dec 21. Available from: https://www.verywellhealth.com/explaining-mrna-vaccines-experts-social-media-5092888.
10. Chauhan G, Madou M, Karla S, Chopra V, Ghosh D, Martinez-Chapa S. Nanotechnology for COVID-19: therapeutics and vaccine research. ACS Nano 2020; 14:(7):7760–7782. doi: 10.1021/acsnano.0c04006.
    [Google Scholar]
11. Ogden SA, Ludlow JT, Alsayouri K. Diphtheria Tetanus Pertussis (DTaP) Vaccine. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan. [Updated 2020 Mar 27]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK545173/.
    [Google Scholar]
12. U.S. Food and Drug Administration (FDA). Conduct of clinical trials of medical products during the COVID-19 public health emergency [Internet]. 2020. [Updated 2021 Jan 27]. Available from: https://www.fda.gov/media/136238/download.
13. Singh K, Mehta S. The clinical development process for a novel preventive vaccine: an overview. J Postgrad Med 2016; 62:(1):4–11. doi:10.4103/0022-3859.173187.
    [Google Scholar]
14. Sharma O, Sultan AA, Ding H, Triggle CR. A review of the progress and challenges of developing a vaccine for COVID-19. Front Immunol 2020; 11::585354. doi:10.3389/fimmu.2020.585354.
    [Google Scholar]
15. National Institutes for Health. Phase 3 clinical trial of investigational vaccine for COVID-19 begins [Internet]. 2020 Jul 27. Available from: https://www.nih.gov/news-events/news-releases/phase-3-clinical-trial-investigational-vaccine-covid-19-begins.
16. The College of Physicians of Philadelphia. Vaccine development, testing, and regulation. The history of vaccines [Internet]. [updated 2018 Jan 17]. Available from: https://www.historyofvaccines.org/content/articles/vaccine-development-testing-and-regulation.
17. Conduct of clinical trials of medical products during the COVID-19 public health emergency. The Food and Drug Administration (FDA) [Internet]. Available from: https://www.fda.gov/media/136238/download.
18. Business Wire. Pfizer and BioNTech conclude phase 3 study of COVID-19 vaccine candidate, meeting all primary efficacy endpoints [Internet]. 2020 Nov 18. Available from: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine .
19. Baden LR, El Sahl HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021; 384::403–416. doi: 10.1056/NEJMoa2035389.
    [Google Scholar]
20. Jackson LA, Neuzil KM, Baggs J, Davis RL, Black S, Yamasaki KM, et al. Compliance with the recommendations for 2 doses of trivalent inactivated influenza vaccine in children less than 9 years of age receiving influenza vaccine for the first time: a vaccine safety datalink study. Pediatrics 2006; 118:(5):2032–2037. doi: 10.1542/peds.2006-1422.
    [Google Scholar]
21. World Health Organization. HPV – facts about the virus, the vaccine and what this means for you [Internet]. Available from: https://www.euro.who.int/__data/assets/pdf_file/0003/356844/QA_HPV_Young-people_EN.pdf?ua = 1.
22. World Health Organization. Accelerating a safe and effective COVID-19 vaccine [Internet]. 2020. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/accelerating-a-safe-and-effective-covid-19-vaccine.
23. Centers for Disease Control and Prevention. Interim clinical considerations for use of mRNA COVID-19 vaccines currently authorized in the United States [Internet]. [updated 2021 Jan 21]. Available from: https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html.
24. Understanding how vaccines work. Center for Disease Control and Prevention [Internet]. Available from: https://www.cdc.gov/vaccines/hcp/conversations/downloads/vacsafe-understand-color-office.pdf.
25. CDC COVID-19 Response Team, Food and Drug Administration. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine – United States, December 14–23, 2020. MMWR Morb Mortal Wkly Rep 2021; 70::46–51. doi: 10.15585/mmwr.mm7002e1.
    [Google Scholar]